Drug intelligence / Profile preview

JX-970

Development stage: Preclinical
Lead developer: SillaJen
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral, Intravenous

Overview

JX-970 is an oncolytic virus derived from the Western Reserve strain of vaccinia virus, engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been further modified by deleting the thymidine kinase (TK) and vaccinia growth factor (VGF) genes, which enhances its tumor selectivity and safety profile. In preclinical studies, JX-970 demonstrated significant tumor debulking efficacy with a strong preference for targeting tumor tissues. The expression of GM-CSF is intended to stimulate anti-tumor immune responses in addition to direct oncolysis. The drug is being developed primarily for the treatment of solid tumors[1][4][7].

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)

Beyond the preview

Go deeper on JX-970.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JX-970.

Explore the full profile